Since 1981, HIV has made a great concern over every national blood program in the world. It creates not only a major medical impact, but also a major social issue. No other diseases except HIV/ AIDS has ever received such a strong support for human right. The knowledge of HIV, however, is still at the tip of an iceberg. Decision making upon HIV/AIDS issue has always been caught in the dilemma, especially in transfusion area. One example is whether to inform the donor when test result of a donor is positive for anti-HIV. On the one hand, sympathy to the donor must be given, then the test result must be kept confidential. On the other hand safety of blood supply must be maintained, then the donor's test result must be informed so that future donation is permanently deferred. Another example is whether HIV antigen screening should be implemented concurrently with anti-HIV in order to maximize blood safety. Cost effectiveness then becomes an issue.
In Thailand new HIV infection as well as total infection is high. Transfusion associated HIV from screened blood during window period is evident. HIV antigen screening is therefore mandatory. In fact, we began HIV antigen screening since September 1991, few years before it was adopted as blood screening policy in the United States. We therefore would like to take this opportunity to share our experience. Thailand's Health Care Profile (Table 1) Thailand is the country of 60 million population.
Health services are provided through a governmental as well as a non-governmental system. There are 100,100 hospital beds throughout the country, 24,000 of which are in Bangkok (1993 census 3. Before dispatch for use, every unti of blood must be tested according to the set standard to maximize the safety of blood.
4. Appropriate use of blood must be encouraged.
5. User (clinicians) and providers (BTS) must be mutually cooperative to maximize blood collection and minimize wastage. Whilst the Sentinel Seroprevalence Surveillance System monitors the trends of the HIV/AIDS epidemic. In AIDS Voluntary Reporting System, health institutions and physicians are encouraged to report the specific details of AIDS cases anonymously to public health authority. In Sentinel Sero-prevalence Surveillance System, cross sectional HIV serosurvey among prostitutes, male attending sexually transmissible diseases (STD) clinics, pregnant women and blood donors, were conducted twice a year (June and December).
In the first 4 years (1984-88), there had been only 19 AIDS cases reported to the Ministry of Public Health. By the end of 1995, a total of 36,500 cumulative AIDS cases have been reported, 14,951 of which occurred in 1995 alone, which is an explosive situation. Most frequent age group is 25-29 among the male and 20-24 among the female. The sex ratio, Table 2 Production at NBC, 1996 Sept. 1984 -Dec. 1996 male: female, is 5. Voluntary self exclusion is another measure for safe blood donation. New as well as regular donors are asked to indicate whether their blood are "safe"
or "unsafe". The result at our center is interesting ( 3. It is then confirmed with Western Blot (WV) if any of the repeat test is positive. Note: When the repeat tests are both positive (ELISA and PA), WB is almost always positive; thus WB is not necessary in this case, since it is an expensive test. 4. Results are transferred to computer with a flag, to alert our staff not to accept future donation and also to keep the donor's result confidential.
All units of blood which are positive for anti-HIV screening are discarded. They are, however, subjected to further repeat testing and confirmation, as described above. Those with negative Western Blot may be put on the lists for re-entry evaluation. Donors with positive results will be notified with consent (optional), and be advised not to donate blood. We also provide counseling to them.
Anti-HIV positive rate in 1996 is as follows; 0.22% for all donations (which decreases from 0.32% in 1994) 1.01% for first time male donors and 0.37% for first time females 0.19% for repeat male donors and 0.09% for repeat females The anti-HIV positive rate in donated blood was The current scheme of HIV-antigen screening is as follows:
1. Abbot HIV Ag-1 monoclonal or Coulter HIV Ag Assay ELISA was used for initial screening. 2. If reactive, they are re-tested in duplicate with the same reagent, but with neutralization. Confirmation of positive result required more than 50% neutralization as compared to control. During 1991-1996, there were a total of 1, 536, 396 cumulative units of blood tested for HIV antigen in concurrence with anti-HIV. Of these, 114 units were positive for HIV antigen; 81 were also anti-HIV positive and 33 were anti-HIV negative. The total HIV antigen positive rate was 7.45 per 100,000 donations. Nearly equal positive rate (52% v. s. 48%) were from first-time donors and repeat donors.
There were a total of 33 HIV-antigen positive but anti-HIV negative (infectious window) among 1, 536, 396 donations. An average infectious window prevalence was 2.15 per 100,000 donations. It was highest (3.1 per 100,000) in 1991-92 when anti-HIV seroconversion rate was also highest (355/100,000 person-year). The prevalence slowly came down each year in concordance with the lower anti-HIV seroconversion rate. The prevalence was 1.49/100,000 in 1996 when anti-HIV sero-conversion rate was 165/ 100,000 person-year. Young male donor was the most predominant group (88%). Associated infectious disease markers were positive at a rather insignificant rate which is unlikely to be useful to use as surrogate markers. Busch8) recently reported a very low anti-HIV sero-conversion in the United States of 3.4/100,000 person-year comparing to our experience in Thailand. This would explain the absence of HIV antigen positive-antibody negative in earlier US study.
With an estimated figure of 80,000-100,000 new HIV infection a year9) in our country, the presence of HIV infectious "window" is therefore expected and the use of HIV-antigen screening is thus definitely useful in our situation, although it costs more. It has been a debating issue whether HIV-antigen screening is cost effective. We consider that cost effectiveness lies not upon the test and its result, but upon the appropriate use of blood. Nevertheless, our analysis9) did show that the addition of HIV-antigen test for the prevention of HIV transmission, even at such low rate of 2.15 per 100,000, is cost benefit in terms of medical care expense, productivity loss and loss of future earnings. Moreover, it prevents the psycho-social cost of pain, suffering, and social stigmatization of the patient.
Risk of transfusion associated HIV in Thailand has significantly decreased after the implementation of HIV antigen screening along with the anti-HIV screening. The risk decreased from 35 to 0.2 per 100,000 (Table 8)  Conclusion In Thailand where HIV infection rate is high, the use of HIV antigen screening in addition to anti HIV has objectively shown to decrease the risk of transfusion associated HIV. Thus, HIV antigen test helps save the economical loss of the country. It also 
